Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play [Seeking Alpha]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Seeking Alpha
The company had a rough year in 2023, making a $4.7bn loss, after an $8bn profit in the prior year. With sales of SpikeVax destined to fall further in 2024, the company needs to deliver fresh commercial vaccines. CMV, RSV, Shingles, Flu, and EBV are all realistic opportunities with near-term RSV and CMV approval shots in play. Moderna's MD believes there is a $50bn total addressable market in play and is typically bullish, but nothing is guaranteed. This is a finely balanced investment opportunity with many strengths and weaknesses to consider. Investment Overview Moderna, Inc. NASDAQ: MRNA ) held an investor event today to review its vaccines program and provide key business updates. Before we dive into that, let's quickly review recent performance. The company announced its Q4 and full year 2023 earnings and business updates on February 22nd. Moderna described 2023 as a "difficult year of transition to a seasonal endemic market," and that is hardly surprising, as, in 20
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing [Yahoo! Finance]Yahoo! Finance
- U.K. Tests World-First Personalized Skin Cancer Vaccine [Forbes]Forbes
- Should You Buy Moderna Before May 12? [Yahoo! Finance]Yahoo! Finance
- Sunil Wadhwa Joins Kong as Chief Customer Officer [Yahoo! Finance]Yahoo! Finance
- Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 2/22/24 - Beat
MRNA
Sec Filings
- 4/26/24 - Form 4
- 4/24/24 - Form 144
- 4/19/24 - Form 4
- MRNA's page on the SEC website